EGFR and cancer: In this study, we employed wtEGFR-expressing and gefitinib-sensitive A431 epidermoid cell line and its gefitinib-resistant derivative, A431/GR [21] to address whether BCRP/ABCG2 plays a role in determining EGFR-TKI sensitivity in wtEGFR-expressing cancer cells.